Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Biocartis Group NV

BioFire Diagnostics provides syndromic infectious disease diagnostics, focusing on rapid and accurate molecular testing.

Kirk Ririe

Carl Wittwer

Randy Rasmussen

BioFire Diagnostics

Spekle Solutions specializes in shaping market access and commercial strategies for life sciences. The company uses advanced analytical techniques and technology to provide customized solutions and insights.

Spekle Solutions

Biocartis develops and offers the Idylla platform for rapid molecular testing in oncology and infectious diseases, focusing on automated testing solutions.

Metric
Company Name	Biocartis Group NV	BioFire Diagnostics	Spekle Solutions
Symbol	BCART
MSH ID	COM:BIOCARTIS	COM:BIOFIREDX	COM:SPEKLESOLUTIONS
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Commercial & Professional Services
Industry	Medical - Diagnostics & Research	Medical Diagnostics	Consulting
Country	BE	US	US
Stage		Venture Round
Employee Count	526	781
Website	biocartis.com	biofiredx.com	speklesolutions.com
LinkedIn		biofire-diagnostics-inc
Founders

Metric
Market Cap	28.77M
Enterprise Value
Monthly Web Traffic		81.66K
Web Traffic Growth		10.40
Valuation
Raised Capital		45M

Metric
Revenue	60.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit	29.24M
EBITDA	-46.11M
Operating Income	-49.38M
Net Income	-69.06M
EPS	-1.14
Diluted EPS	-1.14
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.32
Operating Profit Margin	-0.71
EBITDA Margin	-0.76
Net Profit Margin	-1.11
Return on Equity	1.81
Return on Assets	-0.74
Return on Capital Employed	-0.67

COM:BIOCARTIS

Biocartis

Last Close

0.29

23/07 20:00

Market Cap

27.24M

Beta: -

Volume Today

112.23K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.27
P/B Ratio	-0.58
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.36
EV Multiple	2.43

Metric
Days Sales Outstanding	165.75
Days Payables Outstanding	143.89
Days Inventory Outstanding	127.62
Operating Cycle	238.75
Cash Conversion Cycle	189.50
Asset Turnover	0.81

Metric
Operating Cash Flow	-47.38M
Free Cash Flow	-49.42M
Cash Flow to Debt	-0.42
Operating Cash Flow/Sales	-0.82
Free Cash Flow Yield	-1.72

Metric
Cash & Equivalents	26.33M
Accounts Receivable	1.67M
Inventory	19.97M
Goodwill
Debt to Capitalization	1.55
Debt to Assets	1.07
Current Ratio	1.65
Quick Ratio	1.49

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.67
SG&A to Revenue	0.06